FDA PCAC Hearing July 2026: What's at Stake for Compounded Peptide Access
By
July 23-24, 2026: Pharmacy Compounding Advisory Committee
Summary
This article covers the upcoming July 23-24, 2026 FDA Pharmacy Compounding Advisory Committee (PCAC) hearing on peptides nominated for the 503A compounding list. The outcome will determine whether physicians and pharmacists can continue to access safe, regulated compounded peptides for patients. The piece serves as a hub for following the hearing, understanding its implications for patient access and cost, and taking action by filing public comments before the July 22, 2026 deadline.
Source
Twitter / XFDA PCAC Hearing July 2026: What's at Stake for Compounded Peptide Accesspepmed.orgKey quotes
· 3 pulledThe outcome shapes whether physicians and pharmacists keep access to safe, regulated compounded peptides for their patients.
The decision affects patient access, cost, and whether care stays in regulated channels rather than an unregulated gray market.
Public comments close July 22, 2026.
You might also wanna read
FDA Scientists Find Insufficient Evidence for Peptides, Undercutting RFK Jr.'s Push for Expanded Access
FDA career scientists have determined there is insufficient evidence to support the safety and efficacy of peptides being considered for pro
medpagetoday.com·3d ago
FDA Panel on Peptide Drugs Includes Experts with Financial Ties to Unproven Chemical Industry
The FDA has announced participants for an upcoming meeting to reconsider the safety and effectiveness of controversial peptide drugs. The pa
medpagetoday.com·5d ago
RFK Jr. pushes peptide deregulation; FDA scientists cite lack of safety evidence
Health Secretary Robert F. Kennedy Jr. is pushing to deregulate several peptides, making them more accessible through compounding pharmacies
nbcnews.to·4d ago
FDA Announces Plans to Restrict Non-Approved GLP-1 Drugs in Compounded Medications
The FDA is announcing its intent to take action against non-FDA-approved GLP-1 drugs, specifically targeting GLP-1 active pharmaceutical ing
fda.gov·4mo ago
Pharmaceutical industry embraces cyclic peptides as FDA fast-tracks Merck's candidate
The article discusses the growing interest in cyclic peptides within the pharmaceutical industry, highlighted by Merck & Co.'s cyclic peptid
cen.acs.org·26d ago
FDA Announces Loosened Restrictions on Synthetic Peptide Use in Children
The FDA announces it has loosened restrictions on dousing children with synthetic peptides, with the commissioner stating that while the eff
The Onion·2mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.